Globally, over many years, one of the top drugs for the treatment of HIV/AIDS is Genvoya, marketed by Gilead. In 2024, Genvoya still generated around 1.8 billion U.S. dollars in revenue. Biktarvy, also marketed by Gilead, was the best-selling HIV/AIDS treatment and generated around 13.4 billion U.S. dollars in revenue. Gilead is the drug manufacturer most specialized in developing drugs for the treatment of HIV/AIDS. HIV/AIDS cases worldwide HIV is a virus that attacks the immune system, leading to an increased risk of infections and can lead to death. HIV/AIDS first appeared in global populations in the 1980s. According to current estimates, the prevalence of HIV is highest in low and middle income countries. Eswatini, followed by Lesotho, had the highest rates of HIV infections in 2023. The number of new HIV infections by world region is highest among residents of Eastern and Southern Africa. Access to HIV/AIDS treatment Effective treatment for HIV was not available until the early 1990s. Access to therapy has increased since the early 2000s, and as of 2022 there were approximately 30 million people that had access to antiretroviral therapy. Among countries around the world, Uganda, India and Kenya, to name a few, have the lowest rates of access to antiretroviral medications for the treatment of HIV/AIDS.

Globally, over many years, one of the top drugs for the treatment of HIV/AIDS is Genvoya, marketed by Gilead. In 2023, Genvoya generated some two billion U.S. dollars in revenue. Biktarvy, also marketed by Gilead, was the best-selling HIV/AIDS treatment and generated around 11.9 billion U.S. dollars in revenue. Gilead is the drug manufacturer most specialized in developing drugs for the treatment of HIV/AIDS.

HIV/AIDS cases worldwide

HIV is a virus that attacks the immune system, leading to an increased risk of infections and can lead to death. HIV/AIDS first appeared in global populations in the 1980s. According to current estimates, the prevalence of HIV is highest in low and middle income countries. Eswatini, followed by Lesotho, had the highest rates of HIV infections in 2022. The number of new HIV infections by world region is highest among residents of Eastern and Southern Africa.

Access to HIV/AIDS treatment

Effective treatment for HIV was not available until the early 1990s. Access to therapy has increased since the early 2000s, and as of 2022 there were approximately 30 million people that had access to antiretroviral therapy. Among countries around the world, Uganda, India and Kenya, to name a few, have the lowest rates of access to antiretroviral medications for the treatment of HIV/AIDS. Meanwhile, trends indicate that children living with HIV in Asia or the Pacific have some of the highest rates of access to antiretroviral therapy globally.